Zimmer Trabecular Metal Total Ankle PMCF
Condition(s) studied
Investigational drug(s) / intervention(s)
Zimmer Trabecular Metal Total Ankle System: Primary or revision total ankle replacement
Study summary
The primary objective of this study is to obtain implant survivorship and clinical outcome data for commercially available Zimmer Trabecular Metal Total Ankle implants used in primary or revision total ankle arthroplasty. The assessment will include implant survivorship and clinical performance measured by pain and function, quality of life data, radiographic parameters and survivorship.
Eligibility
Primary outcome measure(s)
- Survivorship — 10 years
Survival of the implants after 10 years which is based on removal of the prosthesis and will be determined using the Kaplan Meier Method.
Trial sites (11)
| Facility | City | Region | Status |
|---|---|---|---|
| University California Davis | Sacramento | California | |
| Orthopaedic Associates of Grand Rapids REI | Grand Rapids | Michigan | |
| OrthoCarolina Research Institute | Charlotte | North Carolina | |
| Duke University | Durham | North Carolina | |
| The Rothman Institute | Philadelphia | Pennsylvania | |
| UBC Providence Health Care Research Institute | Vancouver | British Columbia | |
| Turku University Hospital Finland | Turku | Finland | |
| Klinikverbund St. Antonius und St. Josef GmbH | Wuppertal | Germany | |
| Humanitas San Pio X | Milan | Milano MI | |
| Inselspital-Stiftung Universitatsspital Bern | Bern | Switzerland | |
| Spital StS AG | Thun | Switzerland |
More Zimmer Biomet trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02038140 on ClinicalTrials.gov ↗ ← All trials in the USA